

## Data Sharing Statement

Rosenstock et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk [published online November 9, 2018]. *JAMA*. doi:10.1001/jama.2018.18269

### Data

**Data available:** Yes

**Data types:** Other (please specify)

**Additional Information:** Will be made available upon reasonable request in adherence with open sharing practice

**How to access data:** Data related to the specific manuscript will be made available upon reasonable request in adherence with transparency conventions in medical research and through requests to the corresponding author (juliorosenstock@dallasdiabetes.com). The steering committee of CARMELINA has predeveloped a comprehensive analysis plan and pre-specified numerous analyses, that will subsequently be followed by scientific presentations and publications. The full database will at a later timepoint be made available in adherence with the ratified transparency policy which is detailed here: [https://trials.boehringer-ingenelheim.com/transparency\\_policy.html](https://trials.boehringer-ingenelheim.com/transparency_policy.html).

**When available:** With publication, beginning date: 12-01-2020

### Supporting Documents

**Document types:** None

### Additional Information

**Who can access the data:** Researchers whose proposed use of the data has been approved

**Types of analyses:** For clinical scientific interpretation and publication

**Mechanisms of data availability:** After approval from the steering committee and later after approval from the committee that steers the access according to the transparency policy

**Any additional restrictions:** See datasharing statement